Bristol-Myers Squibb: News
 
Partnering News
March 20, 2017Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody™ Therapeutics for the Treatment of Cancer and Other DiseasesMarch 1, 2017Bristol-Myers Squibb Expands Focus on Precision Medicine with Investment and Planned Collaboration with GRAIL on Blood-Based Cancer ScreeningFebruary 21, 2017First Comprehensive Pediatric Hematology-Oncology Initiative Launched in AfricaJanuary 20, 2017Bristol-Myers Squibb and Ono Pharmaceutical Company Enter Settlement and License Agreement with Merck to Resolve PD-1 Antibody Patent LitigationJanuary 6, 2017Bristol-Myers Squibb and GeneCentric Diagnostics Announce Exploratory Biomarker Research CollaborationJanuary 5, 2017Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration with Janssen to Evaluate Opdivo (nivolumab) in Combination with Darzalex (daratumumab)December 21, 2016Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell CarcinomaDecember 20, 2016Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncolytic Virus to Address Solid TumorsNovember 16, 2016Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive MoleculesNovember 10, 2016Bristol-Myers Squibb Enters into New Collaboration with Johns Hopkins Focused on Immuno-Oncology ResearchNovember 10, 2016Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASHNovember 9, 2016Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with IPI-549 in Advanced Solid TumorsSeptember 27, 2016Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214July 26, 2016Bristol-Myers Squibb Announces New Research Collaboration with Janssen in Immuno-Oncology Focused on Lung CancerJuly 25, 2016AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy RegimenJuly 5, 2016Bristol-Myers Squibb Acquires Cormorant PharmaceuticalsJune 30, 2016Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and EnadenotucirevApril 1, 2016Bristol-Myers Squibb Completes Previously Announced Acquisition of Padlock Therapeutics, Inc.March 23, 2016Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc.February 16, 2016Bristol-Myers Squibb and Dana-Farber Cancer Institute Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research ProgramFebruary 1, 2016Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in JapanDecember 18, 2015Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV HealthcareDecember 14, 2015Bristol-Myers Squibb and UCLA Enter into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research ProgramDecember 8, 2015Bristol-Myers Squibb Completes Previously Announced Acquisition of Cardioxyl Pharmaceuticals, Inc.December 8, 2015Bristol-Myers Squibb Establishes Center for Molecular Synthesis in New Collaboration with Princeton University
 
 
 
 


You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.
You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.